4-Aethylamino-3-nitrobenzaldehyd | 42564-42-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Aethylamino-3-nitrobenzaldehyd
• 英文别名: 4-(Ethylamino)-3-nitrobenzaldehyde
• CAS: 42564-42-1
• 化学式: C₉H₁₀N₂O₃
• mdl: MFCD25978152
• 分子量: 194.19
• InChiKey: PCHSNZWEDYOQND-UHFFFAOYSA-N

物化性质

• 沸点：
  351.0±37.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
  申请人：PMV Pharmaceuticals, Inc.

  公开号：US20170240525A1

  公开（公告）日：2017-08-24

  Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

  癌基因和肿瘤抑制基因的突变促成了癌症的发展和进展。本公开披露描述了一种化合物和方法，用于恢复p53突变体的野生型功能。本发明的化合物可以结合突变型p53，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应子的能力。所披露的化合物可用于减少含有p53突变的癌症的进展。
• Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
  申请人：——

  公开号：US20030130306A1

  公开（公告）日：2003-07-10

  Compounds are provided which have the structure 1 wherein Q is C or N, X 1 is CH or N and, A, E, M, G, X 2 , X 3 , X 4 , R 1 , R 2 , R 2a , R 2b , R 2c , R 3 , Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

  提供的化合物具有如下结构 1 其中 Q 是 C 或 N，X 1 是 CH 或 N，以及 A、E、M、G、X 2 , X 3 , X 4 , R 1 , R 2 , R 2a , R 2b , R 2c , R 3 Y、x、m 和 n 如本文所定义，这些化合物可用作抗糖尿病、降血脂和抗肥胖药物。
• SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD
  申请人：Bristol-Myers Squibb Company

  公开号：EP1442028A1

  公开（公告）日：2004-08-04
• BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS
  申请人：PRINCIPIA BIOPHARMA, INC.

  公开号：US20160368908A1

  公开（公告）日：2016-12-22

  The present disclosure is directed to certain inhibitors of RLK and ITK of formula (I), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by inhibition of RLK and ITK.
• US6673815B2
  申请人：——

  公开号：US6673815B2

  公开（公告）日：2004-01-06